Tumor Inflammatory Microenvironment of the Thyroid Cancer: Relationship between Regulatory T-Cell Imbalance, and p-NFΚB (p65) Expression-A Preliminary Study.
CD25
Hashimoto’s thyroiditis
NFkB
inflammatory microenvironment
thyroid cancer
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
28 Oct 2023
28 Oct 2023
Historique:
received:
30
07
2023
revised:
19
10
2023
accepted:
21
10
2023
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
Inflammatory microenvironment is an essential component of all tumors, including thyroid cancer. Autoimmune thyroid diseases are often associated with thyroid cancer. CD25, expressed in Treg cells and B cells, has been found to be associated with autoimmune thyroid diseases and the NFkB pathway is critical to tumor formation, regulating immune-related genes, and pro-inflammatory cytokine. Protein expression of CD25 and NFkB and its phosphorylated form was analyzed by immunohistochemistry in 80 patients with thyroid cancer (10 cases of cancers with Hashimoto's thyroiditis and 70 cases without). CD25 was mainly detected in the nucleus of the inflammatory cells such as in the thyrocytes and neoplastic cells. Protein staining was detected in the T-lymphocytes of the outermost zone of the lymphoid follicles. Moreover, in all cancer alterations, there were a higher level of p-NFkB than in the surrounding tissues. Again, p-NFkB staining was evident in neoplastic cells but not evident in inflammatory cells. Strong inflammatory infiltrate in the tumor microenvironment is correlated with an invasive phenotype. CD25 and p-NFkB levels were statistically significantly overexpressed in cancer cells.
Sections du résumé
BACKGROUND
BACKGROUND
Inflammatory microenvironment is an essential component of all tumors, including thyroid cancer. Autoimmune thyroid diseases are often associated with thyroid cancer. CD25, expressed in Treg cells and B cells, has been found to be associated with autoimmune thyroid diseases and the NFkB pathway is critical to tumor formation, regulating immune-related genes, and pro-inflammatory cytokine.
METHODS
METHODS
Protein expression of CD25 and NFkB and its phosphorylated form was analyzed by immunohistochemistry in 80 patients with thyroid cancer (10 cases of cancers with Hashimoto's thyroiditis and 70 cases without).
RESULTS
RESULTS
CD25 was mainly detected in the nucleus of the inflammatory cells such as in the thyrocytes and neoplastic cells. Protein staining was detected in the T-lymphocytes of the outermost zone of the lymphoid follicles. Moreover, in all cancer alterations, there were a higher level of p-NFkB than in the surrounding tissues. Again, p-NFkB staining was evident in neoplastic cells but not evident in inflammatory cells.
CONCLUSIONS
CONCLUSIONS
Strong inflammatory infiltrate in the tumor microenvironment is correlated with an invasive phenotype. CD25 and p-NFkB levels were statistically significantly overexpressed in cancer cells.
Identifiants
pubmed: 37959281
pii: jcm12216817
doi: 10.3390/jcm12216817
pmc: PMC10647421
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Cancer. 2023 Apr 1;152(7):1290-1303
pubmed: 36082452
Cancer Control. 2022 Jan-Dec;29:10732748221135447
pubmed: 36256588
Nat Rev Cancer. 2013 Mar;13(3):184-99
pubmed: 23429735
Front Endocrinol (Lausanne). 2018 Jun 21;9:314
pubmed: 29977225
Nat Rev Cancer. 2005 Apr;5(4):297-309
pubmed: 15803156
Clin Pathol. 2019 Mar 18;12:2632010X19829251
pubmed: 30911738
Arq Bras Endocrinol Metabol. 2007 Jul;51(5):843-51
pubmed: 17891249
Endocrine. 2019 Dec;66(3):538-541
pubmed: 31004335
Cancer Cell Int. 2021 Jul 20;21(1):387
pubmed: 34284788
J Immunol. 2004 Apr 1;172(7):4059-67
pubmed: 15034017
Biomed Res Int. 2013;2013:683768
pubmed: 24350284
Clin Transl Med. 2023 Jun;13(6):e1298
pubmed: 37317665
MedComm (2020). 2021 Dec 16;2(4):618-653
pubmed: 34977871
Signal Transduct Target Ther. 2021 Jul 12;6(1):263
pubmed: 34248142
PLoS One. 2014 Jan 29;9(1):e85723
pubmed: 24489667
Int J Mol Sci. 2021 Feb 09;22(4):
pubmed: 33572167
Am J Cancer Res. 2012;2(3):286-97
pubmed: 22679559
Diagn Pathol. 2019 Jun 4;14(1):52
pubmed: 31159823
Cancer Cell Int. 2021 Apr 23;21(1):231
pubmed: 33892730
Chem Biol Interact. 2021 May 1;340:109450
pubmed: 33775688